The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post –myocardial infarction heart failure: Trial rationale and study design
Conclusions This novel approach may lead to a new treatment for those with ischemic heart disease suffering from medically refractory heart failure.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Heart | Heart Attack | Heart Disease | Heart Failure | Study